Articles From: UTi Worldwide Reports Fiscal 2015 Third Quarter Results to ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial


LONG BEACH, Calif., Dec.
Sign-up for UTi Worldwide Reports Fiscal 2015 Third Quarter Results investment picks
Nearly 60 Percent of Security Leaders Believe Attackers Have Outstripped Their Organization's Cyber Security Capabilities ARMONK, N.Y. , Dec.
Sign-up for IBM Study: Organizations Struggling to Defend Against Sophisticated Cyber Attacks investment picks
NRG eVgo, a subsidiary of NRG Energy, Inc. (NYSE:NRG), is expanding its comprehensive electric vehicle (EV) infrastructure designed to support EV drivers whenever and wherever they choose to charge - at single family or apartment residences, at work, on the road, or even at the airport to the Atlanta metro area.
Sign-up for NRG eVgo Announces Electric Vehicle Charging Network in Atlanta investment picks
Throughout 2014, prominent organizations recognized global well-being improvement leader Healthways (Nasdaq: HWAY) for the company’s efforts to improve the health and well-being of its employees as well as its surrounding communities.
Sign-up for Healthways Recognized for Exceptional Work Environment, Work Performance and Community Involvement Initiatives investment picks
2014/12/9
http://media.marketwire.com/attachments/201210/90710_Cisco_logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162839&ProfileId=051205&sourceType=1 SAN JOSE CA --
Sign-up for REMINDER: Media Alert: Cisco to Host 2014 Global Editors Conference in San Jose, CA; Live Broadcast Available investment picks
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in a Phase IIa clinical study evaluating whether its investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide symptomatic relief to patients with diabetic gastroparesis.
Sign-up for Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis investment picks
SANTA CLARA, Calif.
Sign-up for Gigamon Appoints Scott Sullivan Vice President of Worldwide Channel Sales investment picks
OpenFlow Data Path Abstraction Version 2.0 Supports Carrier Network Applications IRVINE, Calif.
Sign-up for Broadcom Delivers Next Generation Open Switch Pipeline Specification investment picks
BME, FXCM, SmartTrade Technologies, Triana and Chi-X, add asset and service diversity to financial services ecosystem, cite ease of multi-region deployment for choosing Equinix data centers REDWOOD CITY, Calif.
Sign-up for Equinix Sees Uptick in Globally Deployed Financial Services Customers Spanning Multiple Asset Classes investment picks
Splunk Inc. (NASDAQ: SPLK), provider of the leading software platform for real-time Operational Intelligence, today announced that Forschungszentrum Jülich has selected Splunk® Enterprise as its companywide platform for Operational Intelligence.
Sign-up for Forschungszentrum Jülich Standardizes on Splunk Enterprise investment picks
NCR Corporation (NYSE:NCR) continues to deliver consumer transaction technologies and financial services around the world by installing Somalia’s first-ever automated teller machine (ATM) in Mogadishu, the East African country’s capital, with Salaam Somali Bank .
Sign-up for NCR Brings Consumer Transaction Technologies around the World investment picks
Bungie and Activision Publishing, Inc., a wholly owned subsidiary of Activision Blizzard, Inc. (Nasdaq: ATVI), announced today that Destiny Expansion I: The Dark Below is now available for download on PlayStation®4, PlayStation®3 computer entertainment system, Xbox One and Xbox 360.
Sign-up for Destiny Universe Expands with Release of Destiny Expansion I: The Dark Below investment picks
ROCKVILLE, Md.
Sign-up for Choice Hotels Reveals 2015 Travel Trends investment picks
Robert Shallish to Retire as Executive VP, Finance and CFO Effective March 31, 2015; Luke Pomilio Appointed Executive VP, Finance and CFO Effective April 1, 2015 UTICA, New York, Dec.
Sign-up for CONMED Corporation Announces Management Transitions investment picks
BEIJING , Dec.
Sign-up for Vimicro's Taiyuan Facility Begins Mass Production investment picks
New cloud offering adds mobile digital engagement capability to Upland's Enterprise Work Management strategy AUSTIN, Texas , Dec.
Sign-up for Upland Software to Acquire Mobile Commons investment picks
PARAMUS, N.J. and BUFFALO, N.Y. , Dec.
Sign-up for Hudson City Bancorp, Inc. And M&T Bank Corporation Announce Further Extension Of Time To Complete Proposed Merger To April 30, 2015 investment picks
2014/12/9
- IND cleared by U.S. Food and Drug Administration - Phase 2 study planned for first-half 2015 - Data from first patient cohort expected second-half 2015 SAN DIEGO , Dec.
Sign-up for Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure investment picks
KPMG Veteran Glenn Farrell Named New Chief Financial Officer EMERYVILLE, Calif.
Sign-up for National MI CFO Jay Sherwood Promoted to President investment picks
SAN JOSE, Calif., and SINGAPORE, Dec.
Sign-up for Avago Technologies Announces $0.35 Interim Dividend investment picks
Violin Memory®, Inc. , (NYSE:VMEM), a leading provider of award-winning all-flash storage arrays and appliances delivering application solutions for the enterprise, today announced the worldwide availability of its Oracle Performance Analysis Service (O-PAS™). This innovative and unique tool helps IT professionals remove the complexity of reporting, analyzing and decision-making around Oracle databases to help dramatically lower the costs of their Oracle deployments while increasing Oracle database and associated application performance.
Sign-up for Violin Launches Automated Oracle Performance Analysis Service (O-PAS™) investment picks
http://media.marketwire.com/attachments/200906/438886_oracleresized.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163618&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for Oracle Delivers Increased Session Capacity With New Acme Packet 4600 Midrange Session Border Controller Platform investment picks
Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced that it received a perfect score on the 2015 Corporate Equality Index (CEI) for the second consecutive year.
Sign-up for Huron Consulting Group Earns Perfect Score on 2015 Corporate Equality Index for Second Consecutive Year investment picks
2014/12/9
Initial orders received total $2.8 million; the systems will be used for Advanced Packaging applications MIGDAL HAEMEK, Israel , December 9, 2014 /PRNewswire/ -- Camtek Ltd.
Sign-up for Camtek Wins Head-to-Head Competition to be Supplier of Choice for AOI Systems at Leading Semiconductor Manufacturer investment picks
Jacobs Engineering Group Inc. (NYSE:JEC) announced today that it was selected as a key partner under the United Kingdom’s National Ecological Services Framework (EcoSF2), to provide specialist ecological services to support the UK Environment Agency ’s technical and monitoring responsibilities.
Sign-up for Jacobs Selected by UK Environment Agency for Ecological Services investment picks
Jacobs Engineering Group Inc. (NYSE:JEC) announced today the successful delivery of engineering and consulting services for a new elevated highway linkage in Kuala Lumpur, Malaysia.
Sign-up for Jacobs Delivers Design Services for New Elevated Highway Linkage in Kuala Lumpur investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With a median follow-up of three years for CP-CML patients and nine months overall, Iclusig continues to exhibit responses in patients with the T315I mutation, for whom there is no other approved tyrosine kinase inhibitor (TKI) therapy.
Sign-up for ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain
Sign-up for ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: UTi Worldwide Reports Fiscal 2015 Third Quarter Results to ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent